Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 12/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 9/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 9/20 | 1.00 |
| ▸ | PDE4A | P27815 | 4/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 4/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 4/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2436275 | 1.00 | PDE5A (1.00) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL149366 | 1.00 | PDE5A (1.00) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL149367 | 1.00 | PDE5A (1.00) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL4751642 | 0.80 | PDE5A (0.66) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL4751641 | 0.80 | PDE5A (0.66) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL10201496 | 0.79 | PDE5A (1.00) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL10201620 | 0.79 | PDE5A (0.84) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL236618 | 0.78 | PDE5A (1.00) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL236619 | 0.78 | PDE5A (1.00) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL236620 | 0.78 | PDE5A (1.00) | PDE5APDE3BPDE3APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | claimed |
| US-20100179152-A1 | Novel use for PDE5 inhibitors | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | claimed |
| US-7737147-B2 | Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors | THOMAS THOMAS NADACKAL | 2010-06-15 | — | — | US | claimed |
| EP-1740183-B1 | NOVEL USE FOR PDE5 INHIBITORS | NYCOMED GMBH (DE) | 2009-10-14 | — | — | EP | claimed |
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | SPROUT PHARMACEUTICALS, INC. | 2008-05-01 | — | — | US | claimed |
| US-20070185114-A1 | Novel use for pde5 inhibitors | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | claimed |
| EP-1740181-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-10 | — | — | EP | claimed |
| US-20060204450-A1 | Pharmaceutical Compositions Based On Anticholinergics and PDE 5-Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-14 | — | — | US | claimed |
| EP-1237577-A2 | TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITOR FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Vivus, Inc. (US) | 2002-09-11 | — | — | EP | claimed |
| US-6403597-B1 | PRETREATMENT SEXUAL INTERCOURSE | VIVUS, INC. | 2002-06-11 | — | — | US | claimed |
| EP-1199070-A2 | Use of PDE V inhibitors for improved fecundity in mammals | Pfizer Limited (GB) | 2002-04-24 | — | — | EP | claimed |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | VIVUS, INC. | 2002-03-28 | — | — | US | claimed |
| US-20020004498-A1 | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | DOHERTY PAUL C (US) | 2002-01-10 | — | — | US | claimed |
| WO-2001070211-A2 | L-ARGININE AND PHOSPHODIESTERASE (PDE) INHIBITOR SYNERGISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-09-27 | — | — | WO | claimed |
| WO-2001041807-A2 | TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 2001-06-14 | — | — | WO | claimed |
| EP-1027054-A1 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Vivus, Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| US-6037346-A | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-03-14 | — | — | US | claimed |
| WO-1999021558-A2 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 1999-05-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | PDE5A 27/4885PDE3B 4/4885PDE3A 11/4885 |
| US-20020004498-A1 | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | PDE3A, PDE5A, PDE3B | PDE5A 2/4885PDE3B 3/4885PDE3A 1/4885 |
| US-20060204450-A1 | Pharmaceutical Compositions Based On Anticholinergics and PDE 5-Inhibitors | PDE5A, PDE3A, PDE3B | PDE5A 1/4885PDE3B 3/4885PDE3A 2/4885 |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | PDE5A, PDE3B, PDE3A | PDE5A 1/4885PDE3B 2/4885PDE3A 3/4885 |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | PDE5A 27/4885PDE3B 4/4885PDE3A 11/4885 |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | PDE5A 27/4885PDE3B 4/4885PDE3A 11/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | PDE5A 27/4885PDE3B 4/4885PDE3A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.